Immunogenicity of 9-valent HPV vaccine in immunocompromised children and adolescents

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501413-31-00

Acronym

19042021/22

Enrollment

126

Registered

2022-09-29

Start date

2023-03-07

Completion date

Unknown

Last updated

2023-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunosuppressed patients

Brief summary

Seroconversion of subjects from baseline to month 7 and 12 (anti HPV titers at baseline, month 7 and month 12).

Detailed description

Age, immunosuppression category (HIV, SOT, HSCT, PCT), CD4/CD8 ratio, specific T cell response, TTV viral load

Interventions

DRUGGardasil 9 suspension for injection in a pre filled syringe.Human Papillomavirus 9 valent Vaccine (Recombinant

DRUGadsorbed)

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Seroconversion of subjects from baseline to month 7 and 12 (anti HPV titers at baseline, month 7 and month 12).	—

Secondary

Measure	Time frame
Age, immunosuppression category (HIV, SOT, HSCT, PCT), CD4/CD8 ratio, specific T cell response, TTV viral load	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026